Investors Asset Management of Georgia Inc. GA ADV Has $5.17 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Investors Asset Management of Georgia Inc. GA ADV grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 8,894 shares of the company’s stock after purchasing an additional 630 shares during the period. Eli Lilly and Company accounts for approximately 2.6% of Investors Asset Management of Georgia Inc. GA ADV’s holdings, making the stock its 5th biggest position. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Eli Lilly and Company were worth $5,165,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in LLY. Simon Quick Advisors LLC boosted its stake in Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $363,000. WASHINGTON TRUST Co raised its holdings in shares of Eli Lilly and Company by 16.5% in the fourth quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after buying an additional 2,671 shares during the last quarter. Liontrust Investment Partners LLP acquired a new position in shares of Eli Lilly and Company during the third quarter worth approximately $8,326,000. Finally, Redhawk Wealth Advisors Inc. grew its stake in shares of Eli Lilly and Company by 0.9% during the third quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock valued at $3,752,000 after purchasing an additional 65 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on LLY. Bank of America upped their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Citigroup boosted their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Performance

NYSE:LLY traded down $5.04 on Thursday, hitting $745.73. The company’s stock had a trading volume of 844,605 shares, compared to its average volume of 3,055,587. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a one year low of $367.35 and a one year high of $800.78. The stock has a fifty day moving average of $764.03 and a two-hundred day moving average of $657.67. The firm has a market capitalization of $708.56 billion, a P/E ratio of 129.32, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.09 EPS. Research analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.